These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12608105)

  • 21. CAN DRUGMAKERS LIVE WITHOUT MERGERS?
    Wieczner Y
    Fortune; 2015 Jun; 171(7):39-40. PubMed ID: 26242019
    [No Abstract]   [Full Text] [Related]  

  • 22. A better prescription for drug-development financing.
    Kessel M; Frank F
    Nat Biotechnol; 2007 Aug; 25(8):859-66. PubMed ID: 17687358
    [No Abstract]   [Full Text] [Related]  

  • 23. Bristol-Myers Squibb swallows last of antibody pioneers.
    Allison M
    Nat Biotechnol; 2009 Sep; 27(9):781-3. PubMed ID: 19741612
    [No Abstract]   [Full Text] [Related]  

  • 24. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 25. Roche vows to keep Genentech culture.
    Hayden EC
    Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
    [No Abstract]   [Full Text] [Related]  

  • 26. A reprise for collaborative financing in biotech.
    Ransom J
    Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
    [No Abstract]   [Full Text] [Related]  

  • 27. Make medicine, not war.
    Simons J
    Fortune; 2002 May; 145(10):132-4. PubMed ID: 12025348
    [No Abstract]   [Full Text] [Related]  

  • 28. NeXstar seeks better valuation through disintegration.
    Dorey E
    Nat Biotechnol; 1998 Oct; 16(10):898. PubMed ID: 9788332
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiinfective biotechs face partnering gap.
    Sheridan C
    Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
    [No Abstract]   [Full Text] [Related]  

  • 30. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 31. A bitter pill for one Merck critic.
    McLean B
    Fortune; 2004 Dec; 150(12):58. PubMed ID: 15617422
    [No Abstract]   [Full Text] [Related]  

  • 32. Maturing biotechs turn to pharma's markets.
    Ratner M
    Nat Biotechnol; 2005 Mar; 23(3):269. PubMed ID: 15765067
    [No Abstract]   [Full Text] [Related]  

  • 33. The best companies bare all.
    Jacobs T
    Nat Biotechnol; 2004 Nov; 22(11):1363. PubMed ID: 15529156
    [No Abstract]   [Full Text] [Related]  

  • 34. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 35. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 36. Niche indications could drive higher valuations.
    Ransom J
    Nat Biotechnol; 2006 Dec; 24(12):1457. PubMed ID: 17160028
    [No Abstract]   [Full Text] [Related]  

  • 37. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 38. Analysts, firms pour cold water on SNP Consortium.
    Hodgson J
    Nat Biotechnol; 1999 Jun; 17(6):526. PubMed ID: 10385305
    [No Abstract]   [Full Text] [Related]  

  • 39. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 40. When a long shot is worth a shot.
    Jacobs T; Fischer J
    Nat Biotechnol; 2005 Jul; 23(7):805. PubMed ID: 16003361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.